SHORT-COURSE ISONIAZID AND PYRAZINAMIDE COMPARED WITH 6-MONTH ISONIAZID FOR TUBERCULOSIS PREVENTION IN HIV-INFECTED ADULTS: THE RANDOMIZED CLINICAL TRIAL
Z. M. Zagdyn,
S. I. Dyrul,
S. Shenoi,
G. N. Isaeva,
O. V. Gavrilova,
E. N. Lebedeva,
E. V. Verbitskaya,
M. V. Beltyukov,
A. Yu. Kovelenov,
E. G. Sokolovich
https://doi.org/10.22328/2077-9828-2017-9-3-54-64
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
The aim of the randomized controlled clinical trial was to compare the efficacy of a 3-month regimen of isoniazid and pyrazinamide with that of a 6-month isoniazid in people living with HIV. Results: From the total 624 enrolled patients treatment was completed by 243 patients in short-course group and by 237 ones in IPT group (р=0,9). Adverse events were established in 6,1% of subjects in combined arm and in 6,7% in isoniazid group (р=0,8). After a follow-up 946,2 person-years, 8 person in isoniazid group and 9 person in compared group developed active TB with TB incidence per 100 person-years 1,9 and 1,8 respectively (p>0,05). The Caplan-Meyer TB survival probability for the entire group of participants over the follow up period was 0,1306 without statistical differences. Three subjects were died in isoniazid group and one person — in combined group. Conclusion. Our data may suggest that for preventing tuberculosis in HIV-infected patients, a daily 3-month regimen of isoniazid and pyrazinamide is similar in safety and efficacy to a daily 6-month regimen of isoniazid. This shorter regimen offers practical advantages to patients and tuberculosis control programs, improving patients’ adherence to TB prevention treatment.
About the Authors
Z. M. Zagdyn
Saint-Petersburg Federal Research Institute of Phthisiopulmonology of Health Care Ministry
Russian Federation
Russian Federation
S. I. Dyrul
Leningrad Region AIDS Center
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
S. Shenoi
Yale University, School of Medicine
United States
Connecticut
United States
Connecticut
G. N. Isaeva
Leningrad Region AIDS Center
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
O. V. Gavrilova
Leningrad Region AIDS Center
Russian Federation
Russian Federation
E. N. Lebedeva
Leningrad Region AIDS Center
Russian Federation
Russian Federation
E. V. Verbitskaya
FSBEI HE I.P.Pavlov SPbMU MON
Russian Federation
Russian Federation
M. V. Beltyukov
Saint-Petersburg Federal Research Institute of Phthisiopulmonology of Health Care Ministry
Russian Federation
Russian Federation
A. Yu. Kovelenov
Leningrad Region AIDS Center
Russian Federation
Russian Federation
E. G. Sokolovich
Saint-Petersburg Federal Research Institute of Phthisiopulmonology of Health Care Ministry
Russian Federation
Russian Federation
References
1. Nechaeva O.B. Vliyanie VICh-infektsii na epidemicheskuyu situatsiyu po tuberkulezu v Rossii // Tuberkulez i sotsial'no-znachimye zabole- vaniya. 2015. № 4. S. 69-70. [Nechaeva O.B. HIV affect the TB epidemic situation in Russia. Tuberculosis and Socially-Determined Diseases, 2015, No. 4, pp. 69-70 (In Russ.)].
2. Galkin V.B., Balasanyants G.S., Belilovskii E.M., Yablonskii P.K. Otsenka dinamiki chislennosti zabolevshikh tuberkulezom v stranakh s naibol'shim bremenem tuberkuleza // Meditsinskii al'yans. 2015. № 1. S. 25-26. [Galkin V.B., Balasanyants G.S., Belilovskiy E.M., Yablonskiy P.K. Estimation of the new TB cases in the process in countries with a highest TB burden. Medical Alliance, 2015, No. 1, pp. 25-26 (In Russ.)].
3. Global tuberculosis report 2014. Geneva: World Health Organization, 2015.
4. A guide to monitoring and evaluation for collaborative TB/HIV activities: 2015 revision. Geneva: WHO, 2015, 44 p.
5. WHO policy on collaborative TB/HIV activities. Guidelines for national programs and other stakeholders. Geneva: WHO, 2012, 36 p.
6. Gupta S.S., Granich R., Suthar A.B., Smyth S., Baggaley R., Sculler D., Date A., Desai M.A., Lule F., Raizes E., Blanc L., McClure C., Hirnschall G. Three I’s for HIV/TB and early ART to prevent HIV and TB: policy review of HIV and TB guidelines for high HIV/TB-burden African countries. Nineteenth International AIDS Conference, Washington DC, 2012, WEPDD0205.
7. World Health Organization, Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: WHO, 2015.
8. Khimioprofilaktika tuberkuleza // Metodicheskoe pis'mo № 10-87/14-1 ot 30.05.1962. M., 1962. [Chemoprophylaxis of Tuberculosis. Methodical Letter No. 10-87/14-1 from 30.05.1962, Moscow, 1962 (In Russ.)].
9. Instruktsiya «Khimioprofilaktika tuberkuleza» // Prikaz Ministerstva zdravookhraneniya SSSR ot 24.03.1988 № 06-14/11-14. M., 1988. [Instruction «Chemoprophylaxis of Tuberculosis». Order of the Ministry of Health of the USSR from 24.03.1988 No. 06-14/11-14, Moscow, 1988 (In Russ.)].
10. Profilaktika i lechenie soputstvuyushchikh zabolevanii (tuberkuleza, virusnykh gepatitov i IPPP) u vzroslykh i podrostkov, bol'nykh VICh-infektsiei: Metodicheskie rekomendatsii // Prikaz Minzdravsotsrazvitiya RF ot 29.12.2006 № 7126-RKh. M., 2006. 41 c. [Methodical Guidelines «Prevention and treatment of co-morbidity (tuberculosis, viral hepatitis and STD) among adults and adolescents, infected by HIV». Order of Health Care and Social Support Ministry of Russian Federation from 29.12.2006 No. 7126-PX, Moscow, 2006, 41 r. (In Russ.)].
11. Frolova O.P., Kravchenko A.V., Martynov A.A., Batyrov F.A. Organizatsiya protivotuberkuleznoi pomoshchi bol'nym VICh-infektsiei: posobie dlya vrachei // M.; Tver': Triada. 2007. 120 c. [Frolova O.P., Kravchenko A.V., Martynov A.A., Batyrov F.A. TB control in HIV-infected people: handbook for clinicians. Moscow; Tver: Triada, 2007, 120 p. (In Russ.)].
12. Tursunova N.A., Vorozhtsova M.P. Profilakticheskaya rabota ftiziatra v Gorodskom tsentre po profilaktike i bor'be so SPIDom: Aktual'nye voprosy diagnostiki i lecheniya tuberkuleza / Pod red. Yu.N.Levasheva. SPb., 2005. S. 60-65. [Tursunova N.A., Vorogtsova M.P. TB preventive work of phthisiatrician at the City AIDS Center: Current issues in diagnosis and treatment of tuberculosis. Ed. Yu.N.Levaschov. Saint-Petersburg, 2005, pp. 60-65 (In Russ.)].
13. Belyakova N.V., Frolova O.P., Zolotareva L.V., Novoselova O.A. Analiz sostoyaniya zabolevaemosti tuberkulezom sredi bol'nykh VICh-infektsiei (na primere pyati oblastei Tsentral'nogo federal'nogo okruga) // Epidemiologiya i vaktsinoprofilaktika. 2010. № 5. S. 54-59. [Belyakova N.V., Frolova O.P., Zolotareva L.V., Novoselova O.A. Evaluation of the TB incidence in HIV-infected patients (in frame of five territories in Central Federal Region). Epydemiology and Vaccine Rrevention, 2010, No. 5, rr. 54-59 (In Russ.)].
14. Burlina E.V., Eismont N.V., Podymova A.S., Ryamova E.P. Rezul'taty preventivnogo lecheniya tuberkuleza u bol'nykh s pozdnimi stadiyami VICh-infektsii v Sverdlovskoi oblasti // Tuberkulez i bolezni legkikh. 2011. № 4. S. 74-75. [Burlina E.V., Eysmont N.V., Podymova A.S., Pyamova E.P. Results of TB preventive treatment in HIV-infected patients with proficient stages in Sverdlovskiy oblast. Tuberculosis and Lung Diseases, 2011, No. 4, pp. 74-75 (In Russ.)].
15. Naryshkina S.L., Alekseeva T.V., Revyakina O.V. Khimioprofilaktika tuberkuleza u bol'nykh VICh-infektsiei // Problemy tuberkuleza u bol'nykh VICh-infektsiei. 2013. № 12. S. 49-50. [Naryschkina S.L., Alexeeva T.V., Revyakina O.V. Chemoprophylaxis of TB in HIV infected patients. TB Problems in HIV Infected Patients, 2013, No. 12, pp. 49-50(In Russ.)].
16. Khoroshutina V.V., Belonosova E.N. Opyt provedeniya khimioprofilaktiki tuberkuleza u bol'nykh VICh-infektsiei // Problemy tuberkuleza u bol'nykh VICh-infektsiei. 2013. № 12. S. 50. [Choroshutina V.V., Belonosova E.N. Experience of providing TB chemoprophylaxis in HIV infected patients. TB Problems in HIV Infected Patients, 2013, No. 12, pp. 50 (In Russ.)].
17. Henok Tadesse Ayele, Maaike S.M. van Mourik, Thomas P.A. Debray, Marc J.M. Bonten. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS Med. 2015, November 9, URL: https://doi.org/10.1371/journal.pone.0142290.
18. Akolo C., Adetifa I., Shepperd S., Volmnik J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews, 2010, No. 1, CD000171, https://doi.org/10.1002/14651858.CD000171.pub3.
19. Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., Hackman J., Hackman J., Hamilton C.D., Menzies D., Kerrigan A., Weis S.E., Weiner M., Wing D., Conde M.B., Bozeman L., Horsburgh C.R. Jr., Chaisson R.E. Three months of once-weekly rifapentine and isoniazid for M. tuberculosis infection. N. Engl. J. Med., 2011, No. 365, pp. 2155-2166.
20. Centers of Disease Control and Prevention. Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. Morb. Mortal. Wkly Rep., 2011, Vol. 60, No. 48, pp. 1650-1653.
21. Martinson N.A., Barnes G.L., Moulton L.H., Msandiwa R., Hausler H., Ram M., McIntyre J.A., Gray G.E., Chaisson R.E. New Regimens to Prevent Tuberculosis in Adults with HIV Infection. N. Engl. J. Med., 2011, Vol. 365, No. 1, pp. 11-20.
22. Martinson N.B., Barnes G., Msandiwa R., Moulton L., Gray G., McIntyre J., Pronyk P., Chaisson R.E. Novel regimens for treating latent TB in HIV-infected adults in South Africa: a randomized clinical trial. Program and Abstracts of Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 8-11 February 2009, pp. 36bLB.
23. Gordin F. Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected Persons: An International Randomized Trial. JAMA. J. Am. Med. Ass., 2000, Vol. 283, No. 11, pp. 1445-1450.
24. Whalen C.C., Johnson L.L., Okwera A., Hom D.L., Huebner R., Mugyenyl P., Mugerwa R.D., Ellner J.J. A trail of three regimens to prevent tuberculosis in Ugandan adults infected with the Human Immunodeficiency Virus. N. Engl. J. Med., 1997, No. 337, pp. 12.
25. Belyakov N.A., Levina O.S., Rybnikov V.Yu. Formirovanie priverzhennosti k lecheniyu u bol'nykh s VICh-infektsiei // VICh-infektsiya i immunosupressii. 2013. T. 5, № 1. S. 7-33. [Belyakov N.A., Levina O.S., Rybnikov V.Yu. Forming a treatment adherence in HIV Infected patients. HIV Infection and Immunosuppressive Disorders, 2013, Vol. 5, No. 1, pp. 7-33(In Russ.)].
26. Prikaz MZ i SR RF ot 09.07.07 № 475 «Ob utverzhdenii standarta meditsinskoi pomoshchi bol'nym bolezn'yu, vyzvannoi virusom immu- nodefitsita cheloveka (VICh) (pri okazanii spetsializirovannoi pomoshchi)». M., 2007. [The Medical care standards to patients with diseases caused by human immunodeficiency virus (HIV) (specialized care). Order of the Health Care and Social Support Ministry of Russian Federation No. 475 of July 9, 2007, Moscow, 2007 (In Russ.)].
27. Prikaz MZ i SR RF ot 09.07.07 g. № 474 «Ob utverzhdenii standarta meditsinskoi pomoshchi bol'nym bolezn'yu, vyzvannoi virusom immuno- defitsita cheloveka (VICh)». M., 2007. [The Medical care standards to patients with diseases caused by human immunodeficiency virus (HIV) (outpatient care). Order of the Health Care and Social Support Ministry of Russian Federation No. 474 of July 9, 2007, Moscow, 2007 (In Russ.)].
28. Pape J.W., Jean S.S., Ho J.L., Hafner A. and Johnson W.D. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet, 1993, Vol. 342, No. 8866, pp. 268-272.
29. Churchyard G.J., Fielding K.L., Lewis J.J., Coetzee L., Corbett E.L., Godfrey-Faussett P., Hayes R.J., Chaisson R.E., Grant A.D. A trial of mass isoniazid preventive therapy for tuberculosis control. N. Engl. J. Med., 2014, Vol. 370, No. 4, pp. 301-310.
30. Ayele H.T., van Mourik M.S. and Bonten M.J. Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: are prospective cohort study. BMC Infect. Dis., 2015, Vol. 15, No. 1, pp. 334.
31. Assebe L.F., Reda H.L., Wubeneh A.D., Lerebo W.T. and Lamber S.M. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health, 2015, No. 15, pp. 346.
32. Quigley M.A., Mwinga A., Hosp M., Lisse I., Fuchs D., Porter T. Long term effectof preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS, 2001, No. 15, pp. 215-222.
33. Golub J.E., Saraceni V., Cavalcante S.C., Pacheco A.G., Moulton L.H., King B.S., Efron A., Moors D., Chaisson R.E., Durovi B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV infected patients in Rio de Janeiro, Brazil. AIDS, 2007, No. 21, pp. 1441-1448.
34. Temprano ANRS Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med., 2015, published online Aug 27, https://doi.org/10.1056/NEJMoa1507198.
35. Golub J.E., Pronyk P., Mohapi L., Thsabangu N., Moshabela M., Struthers H., Gray G.E., McIntyre J.A., Chaisson R.E., Martinson N.A. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS, 2009, No. 23, pp. 631-636.
36. Rangaka M.X., Wilkinson R.J., Boulle A., Glynn J.R., Fielding K., van Cutsem G., Wilkinson K.A., Goliath R., Mathee S., Goemaere E., Maartens G. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a andomized double-blind, placebo-controlled trial. Lancet, 2014, No. 384, pp. 682-690.
37. Hosseinipour V.C., Bisson G.P., Miyahara S., Sun X., Moses A., Riviere C., Kirui F.K., Badal-Faesen S., Lagat D., Nyirenda M., Naidoo K., Hakim J., Mugyenyi P., Henostroza G., Leger P.D., Lama J.R., Mohapi L., Alave J., Mave V., Veloso V.G., Pillay S., Kumarasamy N., Bao J., Hogg E., Jones L., Zolopa A., Kumwenda J., Gupta A. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label andomized controlled trial. Lancet, 2016, No. 387, pp. 1198-1209.
38. Samandari T.M., Mosimaneotsile B., Agizew T., Nyirenda S., Tedla Z., Sibanda T., Shang N., Moeti T.L. Randomized, placebo-controlled trial of 6 vs 36 months isoniazid TB preventive therapy for HIV-infected adults in Botswana. Program and Abstracts of Conference on Retroviruses and Opportunistic Infections, San Francisco, US, 16-19 February 2010, pp. 104LB.
39. Grant A.D., Mngadi K.T., van Halsema C.L., Luttig M.M., Fielding K.L., Churchyard G.J. Adverse events with isoniazid preventive therapy: experience from a large trial. AIDS, 2010, November 24, Suppl. 5, pp. 29-36, https://doi.org/10.1097/01.aids.0000391019.10661.66.
40. Saukkonen J.J., Cohn D.L., Jasmer R.M., Schenker S., Jereb J.A., Nolan C.M., Peloquin C.A., Gordin F.M., Nunes D., Strader D.B., Bernardo J. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med., 2006, Vol. 174, No. 8, pp. 935-952.
41. Mindachew M., Deribew A., Tessema F., Biadgilign S. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. BMC Public Health, 2011, No. 11, pp. 916, https://doi.org/10.1186/1471-2458-11-916.
Review
For citations:
Zagdyn Z.M., Dyrul S.I., Shenoi S., Isaeva G.N., Gavrilova O.V., Lebedeva E.N., Verbitskaya E.V., Beltyukov M.V., Kovelenov A.Yu., Sokolovich E.G. SHORT-COURSE ISONIAZID AND PYRAZINAMIDE COMPARED WITH 6-MONTH ISONIAZID FOR TUBERCULOSIS PREVENTION IN HIV-INFECTED ADULTS: THE RANDOMIZED CLINICAL TRIAL. HIV Infection and Immunosuppressive Disorders. 2017;9(3):54-64. (In Russ.) https://doi.org/10.22328/2077-9828-2017-9-3-54-64
Views:
6971
ISSN 2077-9828 (Print)
.png)
Email this article 